Telix Pharmaceuticals Limited (ASX:TLX)
Australia · Delayed Price · Currency is AUD | Market Cap | 4.99B -47.3% |
| Revenue (ttm) | 1.21B +55.6% |
| Net Income | -10.68M |
| EPS | -0.03 |
| Shares Out | 339.11M |
| PE Ratio | n/a |
| Forward PE | 529.05 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 542,925 |
| Average Volume | 1,466,014 |
| Open | 14.80 |
| Previous Close | 14.72 |
| Day's Range | 14.22 - 15.09 |
| 52-Week Range | 8.26 - 27.40 |
| Beta | 0.65 |
| RSI | 47.58 |
| Earnings Date | Aug 19, 2026 |
About Telix Pharmaceuticals
Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatmen... [Read more]
News
EDAP Explores Collaboration with Telix Pharmaceuticals on Prostate Cancer Treatments
EDAP Explores Collaboration with Telix Pharmaceuticals on Prostate Cancer Treatments
Telix, EDAP And Profound Partner To Explore PSMA-PET Imaging In Prostate Cancer Treatment
(RTTNews) - Telix Pharmaceuticals Limited (TLX) has entered into new collaborations to study how PSMA-PET imaging may support emerging, minimally invasive prostate cancer treatment approaches.
Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches
MELBOURNE, Australia and INDIANAPOLIS, May 15, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that it has entered into letters of intent to pur...
New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC
MELBOURNE, Australia and INDIANAPOLIS, May 05, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces the publication of a new independent analysis of ...
Telix Presents Phase 2 OPTIMAL-PSMA Dosimetry Data For TLX597-Tx In Prostate Cancer Treatment
(RTTNews) - Telix Pharmaceuticals Limited (TLX), a commercial-stage biopharmaceutical company, on Thursday presented dosimetry data from the Phase 2 OPTIMAL-PSMA trial for TLX597-Tx in treating metast...
TLX101-Px (Pixlumi®) MAA Accepted in Europe
MELBOURNE, Australia and INDIANAPOLIS, May 01, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the marketing authorization application (MAA...
Telix Pharmaceuticals Transcript: Status update
A next-generation radioligand therapy portfolio is advancing with TLX597-Tx showing low off-target toxicity and high tumor uptake, supporting dose intensification and adaptive dosing in prostate cancer. Early clinical data indicate favorable safety and efficacy, with ongoing trials targeting both advanced and earlier disease stages.
OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer
MELBOURNE, Australia and INDIANAPOLIS, April 30, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces dosimetry results from the randomized Phase 2 O...
Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach
MELBOURNE, Australia and INDIANAPOLIS, April 28, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) announces an educational webinar exploring the evolution of PSM...
ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026
MELBOURNE, Australia and INDIANAPOLIS, April 22, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that safety and tolerability data from the Pros...
Telix Pharma Doses First Patient In Phase 3 IPAX BrIGHT Trial Of TLX101-Tx; Prices $600 Mln Bonds
(RTTNews) - Telix Pharmaceuticals Ltd (TLX, TLZ.AX), a commercial-stage biopharmaceutical company, announced on Wednesday that it has dosed the first patient in the pivotal Phase 3 IPAX BrIGHT trial e...
Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma
MELBOURNE, Australia and INDIANAPOLIS, April 15, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient has been dosed with TLX1...
Fundies feast on Telix Pharmaceuticals block amid $US550m convertible
The bock trade, expected to be finalised overnight, is part of a so-called delta hedging placement usually seen around convertible bonds.
Telix and Regeneron Announce Strategic Radiopharma Collaboration
MELBOURNE, Australia and INDIANAPOLIS and TARRYTOWN, N.Y., April 13, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) and Regeneron Pharmaceuticals, Inc. (NASDAQ...
FDA Accepts NDA for TLX101-Px (Pixclara®)
MELBOURNE, Australia and INDIANAPOLIS, April 10, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the United States (U.S.) Food and Drug Adm...
Telix Strengthens Board with Additional Director Appointments
MELBOURNE, Australia and INDIANAPOLIS, April 09, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces two additional Non-Executive Director (NED) app...
Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement
MELBOURNE, Australia and INDIANAPOLIS, April 07, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) provides a market update on its commercial and operational perf...
Telix Appoints David Gill as Non-Executive Director
MELBOURNE, Australia and INDIANAPOLIS, April 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces the appointment of David Gill as a Non-Executiv...
Telix selects IBA Cyclone® KIUBE to support manufacturing expansion in the U.S.
Louvain-la-Neuve, Belgium– March 20, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world's leading provider of radiopharmaceutical prod...
Telix Pharmaceuticals Transcript: Status update
Revenue guidance for 2026 is set at $950–$970 million, driven by strong growth in prostate cancer imaging and new product launches. Key clinical trials, including BiPASS and ProstACT Global, are advancing, with significant market expansion and innovation in both diagnostics and therapeutics expected.
Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate
MELBOURNE, Australia and INDIANAPOLIS, March 16, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces the resubmission of a New Drug Application (NDA...
ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives
MELBOURNE, Australia and INDIANAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that Part 1 of the ProstACT Global Phase 3 stud...
Telix Pharmaceuticals Transcript: Study update
Part 1 of the ProstACT Global Phase III study showed TLX591 combined with standard therapies for metastatic castration-resistant prostate cancer had an acceptable safety profile, favorable dosimetry, and no new safety signals. These results support advancing to global Part 2 enrollment and regulatory submissions.
Telix Pharmaceuticals Transcript: Status update
PSMA PET/CT imaging is transforming prostate cancer management, with advances in technology and robust gallium supply chains enabling high-throughput, efficient care. Ongoing research and clinical trials are expanding its role, while new tracers and production methods are being evaluated for future integration.
Telix Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
2026 strategy emphasizes investment in late-stage therapeutics, commercial expansion, and innovation, with imminent regulatory filings and new product launches expected to drive growth. Key clinical trials are progressing, and international expansion is underway.